Subsidised Ozempic: who foots the bill for rapid weight loss

Subsidised Ozempic: the public price of losing weight fast

A paradox: a drug designed for type 2 diabetes has become the fast track to shedding pounds. The issue is not just cosmetic: if the treatment is paid for by the taxpayer, the price of the prescription stops being a private matter. Among those watching the phenomenon, adverse effects are increasingly cited, from loss of muscle mass to cases of vision loss, plus a rebound effect that in many cases returns the lost weight with interest.

The mechanism that changes everything

The drug works by slowing stomach emptying and sending satiety signals to the brain. You eat less, and that translates into fewer kilos. But the loss does not distinguish between fat and muscle, and some argue that losing muscle mass works against the outcome. The other side is digestion: with such slow emptying, overindulgence comes at a high price, and not just on the scales.

When the injection is stopped, the odds of regaining the weight are high. The "rebound effect" emerges as the great forgotten factor: no medication replaces habits, and the public system that funds it is left with the bill for a temporary cosmetic change.

Good investment or tidy business?

Those who defend public funding point out that obesity is a chronic disease with high healthcare costs and that semaglutide can reduce associated complications. Critics bring out the calculator: mostly aesthetic use, with documented adverse effects and a high drop-out rate, turns the taxpayer into the "patsy" paying for a passing fad.

Vision also enters the equation: warnings circulate about cases of vision loss associated with the drug, an effect that does not appear in the marketing. Meanwhile, business is booming for the laboratory: growing demand, a high price and a brand that has become synonymous with weight loss.

An uncomfortable question remains: should public healthcare become the credit card of a society impatient to slim down? Time, and the adverse-effect data, will tell whether the shortcut was worth it.